USD 5.02
↓ -0.66 (-11.62%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| AMLX | -11.6 | -26.2 | 40.2 | 135.7 | 168.4 | -59.9 | -72.2 | -72.2 | -72.2 | -72.2 |
| S&P 500 | -0.6 | -0.5 | 1.5 | 9.1 | 13.4 | 32.3 | 27.0 | 92.1 | 191.7 | 33587.3 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | AMLX |
| name | Amylyx Pharmaceuticals, Inc. |
| price | 5.02 |
| changes percentage | -11.6197 |
| change | -0.66 |
| day low | 4.89 |
| day high | 5.51 |
| year high | 19.949 |
| year low | 1.575 |
| market cap | 344110257 |
| price avg 50 | 4.012 |
| price avg 200 | 4.50845 |
| exchange | NASDAQ |
| volume | 2751765 |
| avg volume | 1355403 |
| open | 5.32 |
| previous close | 5.68 |
| eps | -3.82 |
| pe | -1.31 |
| earnings announcement | 2025-02-27T05:00:00.000+0000 |
| shares outstanding | 68547860 |
| timestamp | 2024-11-14 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001658551 | |||
| revenue | 380786000 | 22230000 | 1612.94 |
| gross profit | 355345000 | 19237000 | 1747.20 |
| gross profit ratio | 0.93 | 0.87 | 7.84 |
| research and development expenses | 128187000 | 93450000 | 37.17 |
| operating expenses | 316543000 | 220578000 | 43.51 |
| interest income | 16155000 | 4291000 | 276.49 |
| interest expense | 0 | 4291000 | -100.00 |
| ebitda | 39890000 | -200854000 | 119.86 |
| ebitdaratio | 0.1 | -9.06 | 101.16 |
| operating income | 38802000 | -201341000 | 119.27 |
| operating income ratio | 0.1 | -9.06 | 101.13 |
| net income | 49271000 | -198375000 | 124.84 |
| net income ratio | 0.13 | -8.92 | 101.45 |
| eps | 0.73 | -2.98 | 124.50 |
Revenue Growth: revenue increased to 381 million in 2023 from 22 million in 2022 representing a change of 1612.94%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 355 million in 2023 from 19 million in 2022 representing a change of 1747.2%. This indicates a sales profitability growth, which is a positive sign for the company.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 40 million in 2023 from -201 million in 2022 representing a change of 119.86%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to 39 million in 2023 from -201 million in 2022 representing a change of 119.27%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to 49 million in 2023 from -198 million in 2022 representing a change of 124.84%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 0.73 in 2023 from 0.73 in 2022 representing a change of 124.5%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses decreased to 128 million in 2023 from 93 million in 2022 representing a change of 37.17%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 317 million in 2023 from 221 million in 2022 representing a change of 43.51%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001658551 | |||
| revenue | 416000 | -1022999 | 140.66 |
| gross profit | -393000 | -8648999 | 95.46 |
| gross profit ratio | -0.94 | 8.45 | -111.17 |
| research and development expenses | 21237000 | 23139000 | -8.22 |
| operating expenses | 75268000 | 44786000 | 68.06 |
| interest income | 3098000 | 4069000 | -23.86 |
| interest expense | 0 | 0 | NaN |
| ebitda | -75661000 | -53227000 | -42.15 |
| ebitdaratio | -181.88 | 52.03 | -449.56 |
| operating income | -75661000 | -53435000 | -41.59 |
| operating income ratio | -181.88 | 52.23 | -448.20 |
| net income | -72704000 | -72700000 | -0.01 |
| net income ratio | -174.77 | 71.07 | -345.93 |
| eps | -1.07 | -1.07 | 0.00 |
Revenue Growth: revenue increased to 0 million in 2024Q3 from -1 million in 2024Q2 representing a change of 140.66%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 0 million in 2024Q3 from -9 million in 2024Q2 representing a change of 95.46%. This indicates a sales profitability growth, which is a positive sign for the company.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -76 million in 2024Q3 from -53 million in 2024Q2 representing a change of -42.15%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -76 million in 2024Q3 from -53 million in 2024Q2 representing a change of -41.59%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -73 million in 2024Q3 from -73 million in 2024Q2 representing a change of -0.01%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Research and Development (R&D) Expenses: R&D Expenses decreased to 21 million in 2024Q3 from 23 million in 2024Q2 representing a change of -8.22%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 75 million in 2024Q3 from 45 million in 2024Q2 representing a change of 68.06%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001658551 | |||
| total assets | 517454000 | 391453000 | 32.19 |
| total liabilities | 84022000 | 50846000 | 65.25 |
| total equity | 433432000 | 340607000 | 27.25 |
| cash and cash equivalents | 170201000 | 62526000 | 172.21 |
| short term investments | 201161000 | 284419000 | -29.27 |
| long term investments | 0 | 719000 | -100.00 |
| total current assets | 464666000 | 382133000 | 21.60 |
| total non current assets | 52788000 | 9319999 | 466.39 |
| total current liabilities | 82042000 | 46609000 | 76.02 |
| total non current liabilities | 1980000 | 4237000 | -53.27 |
| common stock | 7000 | 7000 | 0.00 |
| retained earnings | -304949000 | -354220000 | 13.91 |
| total debt | 4237000 | 6277000 | -32.50 |
Total Assets: Total Assets increased to 517 million in 2023 from 391 million in 2022 representing a change of 32.19%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 433 million in 2023 from 341 million in 2022 representing a change of 27.25%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 170 million in 2023 from 63 million in 2022 representing a change of 172.21%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 465 million in 2023 from 382 million in 2022 representing a change of 21.6%. This indicates a better liquidity position.
Retained Earnings: Retained Earnings increased to -305 million in 2023 from -354 million in 2022 representing a change of 13.91%. This indicates an accumulated profits.
Total Debt: Total Debt decreased to 4 million in 2023 from 6 million in 2022 representing a change of -32.5%. This indicates a reduction in overall debt burden.
Total Liabilities: Total Liabilities increased to 84 million in 2023 from 51 million in 2022 representing a change of 65.25%. This indicates an increase in overall liabilities.
Short Term Investments: Short Term Investments decreased to 201 million in 2023 from 284 million in 2022 representing a change of -29.27%. This indicates a decrease in short-term investment holdings.
Total Current Liabilities: Total Current Liabilities increased to 82 million in 2023 from 47 million in 2022 representing a change of 76.02%. This indicates a higher short-term debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001658551 | |||
| total assets | 250713000 | 332162000 | -24.52 |
| total liabilities | 54510000 | 70853000 | -23.07 |
| total equity | 196203000 | 261309000 | -24.92 |
| cash and cash equivalents | 71839000 | 74999000 | -4.21 |
| short term investments | 162556000 | 234813000 | -30.77 |
| long term investments | 0 | 719000 | -100.00 |
| total current assets | 245263000 | 326722000 | -24.93 |
| total non current assets | 5450000 | 5439999 | 0.18 |
| total current liabilities | 53915000 | 70081000 | -23.07 |
| total non current liabilities | 595000 | 771999 | -22.93 |
| common stock | 7000 | 7000 | 0.00 |
| retained earnings | -569146000 | -496442000 | -14.65 |
| total debt | 2567000 | 3141000 | -18.27 |
Total Assets: Total Assets decreased to 251 million in 2024Q3 from 332 million in 2024Q2 representing a change of -24.52%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 196 million in 2024Q3 from 261 million in 2024Q2 representing a change of -24.92%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 72 million in 2024Q3 from 75 million in 2024Q2 representing a change of -4.21%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 163 million in 2024Q3 from 235 million in 2024Q2 representing a change of -30.77%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 245 million in 2024Q3 from 327 million in 2024Q2 representing a change of -24.93%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -569 million in 2024Q3 from -496 million in 2024Q2 representing a change of -14.65%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 55 million in 2024Q3 from 71 million in 2024Q2 representing a change of -23.07%. This indicates a decrease in overall liabilities.
Total Current Liabilities: Total Current Liabilities decreased to 54 million in 2024Q3 from 70 million in 2024Q2 representing a change of -23.07%. This indicates a lower short-term debt burden.
Total Debt: Total Debt decreased to 3 million in 2024Q3 from 3 million in 2024Q2 representing a change of -18.27%. This indicates a reduction in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001658551 | |||
| net change in cash | 107675000 | 12865000 | 736.96 |
| operating cash flow | 11919000 | -179871000 | 106.63 |
| free cash flow | 10678000 | -182397000 | 105.85 |
| capital expenditure | -1241000 | -2526000 | 50.87 |
| depreciation and amortization | 1088000 | 487000 | 123.41 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 37161000 | 21714000 | 71.14 |
| accounts payables | 15882000 | 1854000 | 756.63 |
| inventory | 0 | -9769000 | 100.00 |
| acquisitions net | 0 | 236462000 | -100.00 |
| investments in property plant and equipment | -1241000 | -2526000 | 50.87 |
| net cash used for investing activites | 92053000 | -238988000 | 138.52 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 6858000 | 432447000 | -98.41 |
| common stock repurchased | -3315000 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 3543000 | 431789000 | -99.18 |
| cash at end of period | 170920000 | 63245000 | 170.25 |
| accounts receivables | 0 | -15306000 | 100.00 |
| cash at beginning of period | 63245000 | 50380000 | 25.54 |
Net Change in Cash: Net Change in Cash increased to 108 million in 2023 from 13 million in 2022 representing a change of 736.96%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 12 million in 2023 from -180 million in 2022 representing a change of 106.63%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 11 million in 2023 from -182 million in 2022 representing a change of 105.85%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to -1 million in 2023 from -3 million in 2022 representing a change of 50.87%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Stock-Based Compensation: Stock-Based Compensation increased to 37 million in 2023 from 22 million in 2022 representing a change of 71.14%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 16 million in 2023 from 2 million in 2022 representing a change of 756.63%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 0 in 2023 from -15 million in 2022 representing a change of 100.0%. This suggests that the company is less capable of collecting payments from its customers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001658551 | |||
| operating cash flow | -41570000 | -66580000 | 37.56 |
| free cash flow | -41551000 | -66669000 | 37.68 |
| capital expenditure | 19000 | -89000 | 121.35 |
| depreciation and amortization | 221000 | 208000 | 6.25 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 6803000 | 9570000 | -28.91 |
| accounts receivables | 2361000 | 16260000 | -85.48 |
| accounts payables | -3487001 | -16434999 | 78.78 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 19000 | -89000 | 121.35 |
| net cash used for investing activites | 38816000 | -28961000 | 234.03 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | -1493000 | 47000 | -3276.60 |
| common stock repurchased | 1335000 | -20000 | 6775.00 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 80000 | 27000 | 196.30 |
| net change in cash | -1719000 | -95553000 | 98.20 |
| cash at end of period | 73280000 | 74999000 | -2.29 |
| cash at beginning of period | 74999000 | 170552000 | -56.03 |
Net Change in Cash: Net Change in Cash increased to -2 million in 2024Q3 from -96 million in 2024Q2 representing a change of 98.2%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -42 million in 2024Q3 from -67 million in 2024Q2 representing a change of 37.56%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -42 million in 2024Q3 from -67 million in 2024Q2 representing a change of 37.68%. This indicates an increase in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation decreased to 7 million in 2024Q3 from 10 million in 2024Q2 representing a change of -28.91%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 3 million in 2024Q3 from 16 million in 2024Q2 representing a change of 78.78%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables decreased to 2 million in 2024Q3 from 16 million in 2024Q2 representing a change of -85.48%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Capital Expenditure: Capital Expenditure increased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of 121.35%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 5.66 | 0.33 | 1594.53 |
| net income per share | 0.73 | -2.98 | 124.57 |
| operating cash flow per share | 0.18 | -2.7 | 106.56 |
| free cash flow per share | 0.16 | -2.74 | 105.79 |
| cash per share | 5.52 | 5.22 | 5.89 |
| book value per share | 6.45 | 5.12 | 25.89 |
| tangible book value per share | 6.45 | 5.12 | 25.89 |
| shareholders equity per share | 6.45 | 5.12 | 25.89 |
| interest debt per share | 0.03 | 0.1 | -64.73 |
| market cap | 989691324.8 | 2457618806.45 | -59.73 |
| enterprise value | 823727324.8 | 2401369806.45 | -65.70 |
| pe ratio | 20.09 | -12.39 | 262.14 |
| price to sales ratio | 2.6 | 110.55 | -97.65 |
| pocfratio | 83.03 | -13.66 | 707.72 |
| pfcf ratio | 92.69 | -13.47 | 787.88 |
| pb ratio | 2.28 | 7.22 | -68.35 |
| ptb ratio | 2.28 | 7.22 | -68.35 |
| ev to sales | 2.16 | 108.02 | -98.00 |
| enterprise value over ebitda | 20.65 | -11.96 | 272.72 |
| ev to operating cash flow | 69.11 | -13.35 | 617.66 |
| ev to free cash flow | 77.14 | -13.17 | 685.94 |
| earnings yield | 0.05 | -0.08 | 161.68 |
| free cash flow yield | 0.01 | -0.07 | 114.54 |
| debt to equity | 0.01 | 0.01 | -13.06 |
| debt to assets | 0.0 | 0.01 | -16.30 |
| net debt to ebitda | -4.16 | 0.28 | -1585.65 |
| current ratio | 5.66 | 8.2 | -30.92 |
| interest coverage | 0 | -46.92 | 100.00 |
| income quality | 0.24 | 0.91 | -73.32 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.47 | 5.72 | -91.79 |
| research and ddevelopement to revenue | 0.34 | 4.2 | -91.99 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | 0.1 | -0.01 | 841.41 |
| capex to revenue | 0.0 | 0.11 | -97.13 |
| capex to depreciation | 1.14 | 5.19 | -78.01 |
| stock based compensation to revenue | 0.1 | 0.98 | -90.01 |
| graham number | 10.31 | 18.54 | -44.38 |
| roic | 0.08 | -0.59 | 113.70 |
| return on tangible assets | 0.1 | -0.51 | 118.79 |
| graham net net | 5.01 | 4.7 | 6.55 |
| working capital | 382624000 | 335524000 | 14.04 |
| tangible asset value | 433432000 | 340607000 | 27.25 |
| net current asset value | 380644000 | 331287000 | 14.90 |
| invested capital | 389035000 | 343659000 | 13.20 |
| average receivables | 27678000 | 7653000 | 261.66 |
| average payables | 14159000 | 5314500 | 166.42 |
| average inventory | 24046000 | 4884500 | 392.29 |
| days sales outstanding | 38.39 | 251.31 | -84.72 |
| days payables outstanding | 316.51 | 763.05 | -58.52 |
| days of inventory on hand | 549.82 | 1191.34 | -53.85 |
| receivables turnover | 9.51 | 1.45 | 554.64 |
| payables turnover | 1.15 | 0.48 | 141.08 |
| inventory turnover | 0.66 | 0.31 | 116.68 |
| roe | 0.11 | -0.58 | 119.52 |
| capex per share | 0.02 | 0.04 | -51.40 |
ROE:
PE Ratio: Price-to-Earnings (P/E) Ratio increased to 20.09 on 2023-12-31 from -12.39 on 2022-12-31, representing a change of 262.14%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.01 on 2023-12-31 from 0.01 on 2022-12-31, representing a change of -13.06%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Current Ratio: Current Ratio decreased to 5.66 on 2023-12-31 from 8.20 on 2022-12-31, representing a change of -30.92%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| AMLX | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0.01 | -0.02 | 140.63 |
| net income per share | -1.07 | -1.07 | 0.09 |
| operating cash flow per share | -0.61 | -0.98 | 37.62 |
| free cash flow per share | -0.61 | -0.98 | 37.74 |
| cash per share | 3.44 | 4.55 | -24.42 |
| book value per share | 2.88 | 3.84 | -24.99 |
| tangible book value per share | 2.88 | 3.84 | -24.99 |
| shareholders equity per share | 2.88 | 3.84 | -24.99 |
| interest debt per share | 0.04 | 0 | NaN |
| market cap | 220616285.04 | 127886866.52 | 72.51 |
| enterprise value | 151344285.04 | 56028866.52 | 170.12 |
| pe ratio | -0.76 | -0.44 | -72.50 |
| price to sales ratio | 530.33 | -125.01 | 524.22 |
| pocfratio | -5.31 | -1.92 | -176.30 |
| pfcf ratio | -5.31 | -1.92 | -176.79 |
| pb ratio | 1.12 | 0.49 | 129.75 |
| ptb ratio | 1.12 | 0.49 | 129.75 |
| ev to sales | 363.81 | -54.77 | 764.26 |
| enterprise value over ebitda | -2.0 | -1.05 | -90.03 |
| ev to operating cash flow | -3.64 | -0.84 | -332.63 |
| ev to free cash flow | -3.64 | -0.84 | -333.41 |
| earnings yield | -0.33 | -0.57 | 42.03 |
| free cash flow yield | -0.19 | -0.52 | 63.87 |
| debt to equity | 0.01 | 0 | NaN |
| debt to assets | 0.01 | 0 | NaN |
| net debt to ebitda | 0.92 | 1.35 | -32.18 |
| current ratio | 4.55 | 4.66 | -2.42 |
| interest coverage | 0 | 0 | NaN |
| income quality | 0.57 | 0.92 | -37.57 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 51.05 | -22.62 | 325.70 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.0 | -0.0 | 65.81 |
| capex to revenue | 0.05 | -0.09 | 152.50 |
| capex to depreciation | 0.09 | 0.43 | -79.91 |
| stock based compensation to revenue | 16.35 | -9.35 | 274.81 |
| graham number | 8.32 | 9.61 | -13.43 |
| roic | -0.38 | -0.2 | -86.14 |
| return on tangible assets | -0.29 | -0.22 | -32.49 |
| graham net net | 2.66 | 3.56 | -25.21 |
| working capital | 191348000 | 256641000 | -25.44 |
| tangible asset value | 196203000 | 261309000 | -24.92 |
| net current asset value | 190753000 | 255869000 | -25.45 |
| invested capital | 194875000 | 260883000 | -25.30 |
| average receivables | 2911000 | 12221000 | -76.18 |
| average payables | 3221000 | 13204000 | -75.61 |
| average inventory | 0 | 0.5 | -100.00 |
| days sales outstanding | 374.5 | -359.91 | 204.05 |
| days payables outstanding | 165.43 | 58.48 | 182.89 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0.24 | -0.25 | 196.11 |
| payables turnover | 0.54 | 1.54 | -64.65 |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.37 | -0.28 | -33.19 |
| capex per share | 0.0 | 0.0 | -78.67 |
ROE: Return on Equity (ROE) decreased to -0.37 on 2024-09-30 Q3 from -0.28 on 2024-06-30 Q2, representing a change of -33.19%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -0.76 on 2024-09-30 Q3 from -0.44 on 2024-06-30 Q2, representing a change of -72.50%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 4.55 on 2024-09-30 Q3 from 4.66 on 2024-06-30 Q2, representing a change of -2.42%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-09 10:06:08
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q3 2024 Earnings Call Transcript November 7, 2024 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee - Co-Chief Executive Officer Camille Bedrosian - Chief Medical Officer James Frates - Chief Financial Officer Joshua Cohen - Co-Chief Executive Officer Conference Call Participants Charlie Yang - Bank of America Merrill Lynch Michael DiFiore - Evercore ISI Graig Suvannavejh - Mizuho Securities USA Basma Radwan - Leerink Partners Ananda Ghosh - H.C. Wainwright & Co. Joel Beatty - Robert W.
Sentiment: Positive
Publish Date: 2024-10-18 07:26:55
The company seems to have a winner on its hands with a drug that targets a rare genetic disorder.
Sentiment: Neutral
Publish Date: 2024-10-15 09:00:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024.
Sentiment: Negative
Publish Date: 2024-10-03 15:06:00
NEW YORK, Oct. 3, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Amylyx insiders caused the company to misrepresent or fail to disclose that (i) RELYVRIO's commercial prospects were overstated; (ii) patients were discontinuing treatment with RELYVRIO after six months; (iii) the rate at which new patients were starting treatment with RELYVRIO was decreasing; (iv) accordingly, RELYVRIO's prescription rate was also overstated; (v) insiders attempted to hide the foregoing negative trends from investors and the market by blocking analysts from viewing RELYVRIO's prescription data; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
Sentiment: Positive
Publish Date: 2024-09-16 11:42:00
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders.
Sentiment: Neutral
Publish Date: 2024-08-28 08:30:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in the following upcoming investor conferences, which are being conducted in-person in New York City: Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on Thursday, September 5, 2024, at 1:50pm ET Baird 2024 Global Healthcare Conference: Fireside chat on Tuesday, September 10, 2024, at 3:45pm ET H.C. Wainwright 26th Annu.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
